0

The full content of Annals is available to subscribers

Subscribe/Learn More  >
Articles |

MACOP-B Chemotherapy for the Treatment of Diffuse Large-Cell Lymphoma

PAUL KLIMO, M.D.; and JOSEPH M. CONNORS, M.D.
[+] Article and Author Information

Grant support: Support for the treatment and follow-up of the first 11 patients on this protocol was provided, in part, by the National Cancer Institute of Canada Clinical Trials Group.

Presented in part at the 1983 meeting of the International Congress on Chemotherapy in Vienna, Austria, and at the 1984 meeting of the American Society of Clinical Oncology in Toronto, Ontario.

▸Requests for reprints should be addressed to Joseph M. Connors, M.D.; Cancer Control Agency of British Columbia, 600 West 10th Avenue; Vancouver, British Columbia V5Z 4E6, Canada.


Vancouver, British Columbia, Canada


© 1985 American College of PhysiciansAmerican College of Physicians


Ann Intern Med. 1985;102(5):596-602. doi:10.7326/0003-4819-102-5-596
Text Size: A A A

Between April 1981 and May 1984, 61 patients with advanced diffuse large-cell lymphoma completed treatment with MACOP-B (methotrexate with leucovorin rescue, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin), an innovative pilot chemotherapy program emphasizing weekly treatment, antibiotic prophylaxis, daily corticosteroid treatments, and brief duration (12 weeks). Fifty-one patients (84%) achieved a complete response and 10 patients (16%) had a partial response. Over a median follow-up after treatment of 23 months, the actuarial overall survival for the entire group has been 76%; for complete responders the relapse-free survival has been 90%. Toxicity was modest with one treatment-related death and seven episodes of serious infection. The most frequent toxicity was mucositis. Thus, MACOP-B is an effective treatment for large-cell lymphoma that can be delivered in 12 weeks with an acceptable incidence of toxicity. This regimen can achieve results similar and possibly superior to those of other presently used regimens of longer duration.

Figures

Tables

References

Letters

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Comments

Submit a Comment
Submit a Comment

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

Toolkit

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Advertisement
Related Articles
Journal Club
Topic Collections
PubMed Articles
Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.
(Required)
(Required)